Ficlatuzumab not checked
AVEO Pharmaceuticals, Inc. · AV-299
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).”In the company’s words, NCT06064877 on ClinicalTrials.gov
- Tested for
- Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Main trialPhase 3
- “The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.”In the company’s words, NCT06064877 on ClinicalTrials.gov
- Other names
- AV-299
Other drugs for Metastatic Head-and-neck Squamous-cell Carcinoma
- APG-157Aveta Biomics, Inc. · Phase 3
- PembrolizumabMerck & Co. · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- SYS6002CSPC · Phase 3
- MRG003Lepu Biopharma Co., Ltd. · Phase 3
- IAE0972SUNHO(China)BioPharmaceutical CO., Ltd. · Phase 2/3
Coming up1
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2027 | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026